In This Issue
I n the past few months we have received a gratifying increase in submissions of fine articles to Integrative Cancer Therapies, especially from our international contributors. ICT is beginning to take its place as a truly international publication. This issue contains articles from authors in Canada, Norway, India, Australia, Germany, Iran, and China as well as the United States. The growth of global interest in integrative cancer care is significant and bodes well for the future. We are also pleased that we have articles from all levels of scientific inquiry in this issue: in vitro studies, clinical trials, and review articles.
Our first article is my commentary about the increasing number of suggestions that supplements provide little benefit for reducing cancer risk. This is one of several controversies that have arisen among readers of ICT, and the editorial staff have decided to address these topics in short, formal commentaries. We hope you will provide comments of your own and begin a genuine dialogue that we can include in the journal. I have elected to address supplements and cancer risk because this controversy is tainting the valuable role that nutraceuticals can have in the treatment of cancer. In future issues, I will provide further commentaries on this and related areas of integrative cancer treatment.
The next article is a review by Deborah Kennedy and colleagues. Dr. Kennedy and colleagues are at the Canadian College of Naturopathic Medicine, and it is gratifying to see an excellent contribution from naturopathic physicians in this issue. They review the use of thermography as a tool for breast cancer screenings. Some alternative practitioners have shown interest in using this technique as an alternative to mammography, and the review provides a useful summary of its current status.
We previously published an animal study by Karen Wonders and colleagues at Wright State University on the potential of exercise to retard cardiotoxicity from doxorubicin. These authors now extend this study by further examining the literature and delving into the possibility that exercise is cardioprotective for patients taking Herceptin. Given the large number of breast cancer patients who will be taking either or both of these drugs, this review is of special interest and is certainly timely.
William Ware, an emeritus faculty member of the University of Western Ontario, reviews the properties of bitter-tasting phytochemicals that are metabolized by cytochrome P450 1B1, an enzyme commonly overexpressed in tumor cells. The phytochemicals (one of which is resveratrol) can be converted into cytotoxic compounds within cancer cells by this enzyme, making them into a class of cancer-targeted prodrugs. This may be one of the mechanisms behind the apparent beneficial effects of diets high in fruits and vegetables in cancer patients. This very interesting route of investigation is an important step in understanding the role that resveratrol may play in countering cancer biology.
A research group from the Norwegian University of Science and Technology, under lead author Silje Engdal, has contributed a study of herb-drug combinations used by patients taking both chemotherapy and herbal medicine. These authors examine the potential for harmful herbdrug interactions and include a thorough literature review with their clinical results. The article points out the lack of knowledge about potential interactions for about half of the herbs being taken by these patients.
Yoga for cancer patients has been the subject of several clinical studies. This issue includes an article by Rao Raghavendra and colleagues from the HCG Bangalore Institute of Oncology and other institutions in Karnataka State, India. This is a well-designed trial that features a control group counseling intervention as well as a yoga intervention for breast cancer patients undergoing adjuvant radiotherapy treatment. The statistical analysis is sophisticated, and the outcomes, mood states and cortisol rhythms, are of particular interest.
Our contribution from Australia, authored by Nicola Reavley and colleagues, concerns a 10-day residential program given at The Gawler Foundation that emphasizes meditation, social support, positive thinking, and a lowfat vegetarian diet. The study includes follow-ups immediately after the program and at 6 and 12 months after the program to document a variety of quality of life and dietary adherence variables.
Wolfgang Weidenhammer and colleagues at the TU Munich-Centre for Complementary Medicine Research surveyed cancer patients at a university hospital, investigating both personal use of CAM and potential demand for CAM services within the hospital. Surveying the demand for CAM services is not a widely used approach in CAM studies, but it provides a useful and interesting grounding for hospital administrators who are making decisions about allocating resources to CAM programs.
Shelly Adler and colleagues at the University of California at San Francisco performed a qualitative study in breast cancer patients older than 55 who were simultaneously seeing at least one conventional physician and one CAM practitioner for their cancer management. This qualitative study examines the importance of CAM for this group of women and examines their perceptions of the difference and usefulness of CAM versus integrative medicine.
From Iran comes a clinical study on an herbal-marine extract by investigators at the University of Teheran under the lead author Amrollah Ahmadi. This is a straightforward observational clinical study in metastatic colorectal cancer patients, examining data on safety and quality of life parameters. It typifies the appropriate steps included in clinical trials on anticancer agents: conducting preliminary studies to assess safety and quality of life before moving toward efficacy in prospective and later randomized trials.
Moving to our laboratory-based articles, we begin with a study by Akilesh Kumar and colleagues from the University of Mysore. They examined the properties of allyl isothiocyanate in inhibiting ascites tumor growth, specifically its antiangio genic and proapoptotic features. This article includes a wide variety of assays of antiangiogenic and apoptosis-inducing mechanisms, leading to a deeper understanding of the properties of this important Brassica vegetable compound.
Wu Zhi-Ping and colleagues at Yunnan University conducted a study on the potential of artemether to inhibit growth of gliomas, based on an in vivo model. Given the dearth of therapies available for gliomas, this is an important study. The authors were able to detect an inhibition of microvessel density in tumor tissue of animals exposed to artemether, certainly an early but promising result.
Guruprasad Kalthur and colleagues at Kasturba Medical College have studied a novel approach to increasing the efficacy of hyperthermia therapy for cancer. One of the problems with hyperthermia is that tumors can develop tolerance to high temperatures, reducing their susceptibility to hyperthermia treatment. These authors examine the ability of the protein synthesis inhibitor and antitumor compound withaferin A, a phytochemical derived from the Indian adaptogenic plant Ashwagandha (Withania somnifera), to delay development of thermotolerance, a property that has been recognized in other protein synthesis inhibitors.
Archana Jindal and colleagues from the University of Rajasthan investigated the properties of Emblica officinalis as a radioprotector. This herbal medicine, called Amla in India, is widely used and has been found previously to have antitumor properties. This article is another in a series of preliminary studies on plants with radioprotective properties that ICT has published. These are certainly very early studies and do not include specific evidence about whether the herbs and phytochemicals studied may have tumorprotective properties in addition to normal tissue protection. However, because most of these plants are acknowledged to have tumor-inhibitory properties, we regard them as having interesting potential for future development.
During 2008, we were fortunate to have a large number of excellent scientists participate in peer review and article evaluation. The following were our major reviewers for articles during 2008: William Amalau, A. Ascencao,
